Abstract P1-04-22: Loss of SMAD4 Drives Breast Cancer Invasion and Metastasis through E2F1-Mediated Activation of the PEG10-ERK Axis

Dan Shu, Shengchun Liu, Shuo Li, Meiying Shen, Aishun Jin, Han Li, Xin LiuClinical 2025 · DOI

Abstract

Abstract Objective: Although SMAD4 mutations are rare in breast cancer, its loss is strongly associated with metastasis and poor prognosis. This highlights the need to elucidate the mechanisms by which SMAD4 influences breast cancer progression. In this study, we examined the invasive and metastatic properties of SMAD4-deficient breast cancer cell lines, alongside transcriptomic changes in SMAD4 knockout (KO) models, with the aim of uncovering the molecular pathways through which SMAD4 regulates breast cancer recurrence and metastasis.Methods: We analyzed SMAD4 expression across multiple bioinformatics platforms and in 102 clinical breast cancer samples. Using CRISPR/Cas9, we generated SMAD4-knockout cell lines and conducted both in vitro and in vivo assays to assess the impact of SMAD4 depletion on tumor growth and metastasis. RNA sequencing (RNA-seq) was employed to identify downstream targets and pathways influenced by SMAD4, while Cut&Tag-seq provided direct evidence of SMAD4's role as a transcriptional co-regulator controlling the expression of key target genes.Results: SMAD4 was found to be significantly downregulated in breast cancer samples, with this downregulation correlating with adverse clinicopathological features and increased risk of recurrence and metastasis. Mechanistically, we discovered that SMAD4 suppresses tumor progression via the PEG10/ERK signaling axis. Disruption of PEG10/ERK signaling abrogated the pro-metastatic effects of SMAD4 loss. Further, we demonstrated that SMAD4 interacts with the transcription factor E2F1, enhancing its transcriptional activation of PEG10, which in turn activates ERK signaling and promotes breast cancer cell invasion and metastasis.Conclusion: Our study position SMAD4 as a pivotal transcriptional co-regulator in breast cancer, with important implications for its role as a prognostic biomarker and tumor suppressor. We also underscore the critical contribution of the SMAD4-PEG10-ERK axis in driving breast cancer metastasis, providing potential therapeutic targets for intervention. Citation Format: Dan Shu, Shengchun Liu, Kang Li, Meiying Shen, Aishun Jin, Han Li, Xin Liu. Loss of SMAD4 Drives Breast Cancer Invasion and Metastasis through E2F1-Mediated Activation of the PEG10-ERK Axis [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P1-04-22.
BibTeX
@inproceedings{shu2025abstract,
  author = {Dan Shu and Shengchun Liu and Shuo Li and Meiying Shen and Aishun Jin and Han Li and Xin Liu},
  title = {{Abstract P1-04-22: Loss of SMAD4 Drives Breast Cancer Invasion and Metastasis through E2F1-Mediated Activation of the PEG10-ERK Axis}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1158/1557-3265.sabcs24-p1-04-22},
}

Loading related content...

Figure